MONECO Advisors LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,307 shares of the biopharmaceutical company’s stock after acquiring an additional 688 shares during the quarter. […]
Weaver C. Barksdale & Associates Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 20.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 25,746 shares of the biopharmaceutical company’s stock after selling 6,786 shares during the quarter. Gilead Sciences makes up about 2.0% of Weaver C. Barksdale & Associates Inc.’s […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price reduced by Barclays from $80.00 to $76.00 in a report issued on Monday, Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently weighed in on the stock. Truist Financial cut shares of Gilead […]
Mather Group LLC Boosts Stake in Gilead Sciences, Inc (NASDAQ:GILD) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Concord Wealth Partners boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 34.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 18,355 shares of the biopharmaceutical company’s stock after purchasing an additional 4,684 shares during the period. Concord Wealth Partners’ holdings in Gilead […]